Eli Lilly and Company successfully gained the transfer of canetamounjaro.shop after a WIPO panel found the site was a fake shop impersonating the brand to sell counterfeit pharmaceutical products. The respondent failed to respond to the complaint, confirming the domain was registered and used in bad faith.
Case Snapshot
| Case Number | D2026-3541 |
|---|---|
| Complainant | Eli Lilly and Company |
| Respondent | felipe Matheus Alves dos Santos |
| Disputed Domain | canetamounjaro.shop |
| Threat Tactic | Fake Stores |
| Decision Date | 2026-09-04 |
| Panelist | Philippe Gilliéron |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2026-3541 |
Facing Unauthorized Domain Registrations or Brand Abuse?
Our domain dispute attorneys represent trademark owners and businesses worldwide before WIPO, Forum (NAF), and CAC. Explore our Domain Name Disputes and Enforcement & Takedowns services, or request a free case evaluation.
Request Case EvaluationBusiness and Consumer Trust Risks of Impersonation Fraud
The registration and active use of the domain ‘canetamounjaro.shop’ posed a critical threat to both Eli Lilly and Company’s brand equity and patient safety. By falsely presenting itself as ‘Eli Lilly Brasil® Distribuidora de produtos farmaceuticos,’ the respondent attempted to leverage the reputation of an established pharmaceutical leader to gain the confidence of unsuspecting consumers. This form of corporate impersonation, combined with the illicit offer of prescription-grade products without medical oversight, directly compromises the integrity of the supply chain and risks severe harm to public health. The absence of legitimate contact information further exacerbated the risk, effectively stripping consumers of any recourse and exposing them to potentially hazardous counterfeit medications.
Furthermore, the reliance on AI-generated imagery featuring misspelled branding such as ‘mouryaro’ illustrates an evolving hallmark of digital fraud that exploits customer trust through superficial mimicry. Such tactics are designed to deceive users by providing a veneer of professionalism while minimizing the operational effort required by bad actors. For brand owners, these schemes not only result in direct diversion of traffic but also cause significant erosion of consumer trust, as victims may erroneously attribute the poor quality and lack of medical standards to the pharmaceutical company itself. The systematic use of the MOUNJARO trademark in this deceptive context underscores the necessity for rigorous monitoring of domain registrations to prevent the unauthorized exploitation of proprietary medicinal brands.
Legal Analysis of Confusing Similarity, Lack of Rights, and Bad Faith Registration
The panel determined that the disputed domain name, ‘canetamounjaro.shop’, is confusingly similar to Eli Lilly and Company’s ‘MOUNJARO’ trademark. Despite the inclusion of the Portuguese term ‘caneta’ (meaning ‘pen’), the domain entirely incorporates the protected mark. The panel reasoned that such an addition does not mitigate the risk of consumer confusion regarding the official source of the products offered on the associated website.
Regarding the second pillar of the UDRP analysis, the respondent failed to establish any rights or legitimate interests in the domain. The evidence confirms that the respondent was never authorized, licensed, or otherwise permitted by the complainant to utilize the MOUNJARO trademark in any capacity. Furthermore, the respondent is not known by the name of the domain and does not utilize it for any bona fide commercial offering, rendering their registration a clear violation of legitimate IP interests.
The panel further identified compelling evidence of bad faith registration and use. By creating a fraudulent ‘Eli Lilly Brasil’ storefront to sell counterfeit pharmaceutical products without a prescription, the respondent demonstrated an intentional effort to deceive the public. The presence of AI-generated content containing brand misspellings further illustrates the malicious intent behind the site’s operations. As the respondent did not respond to the complainant’s allegations, the panel concluded that the respondent was fully aware of the complainant’s rights at the time of registration, ultimately mandating the transfer of the domain.
Strategic Enforcement Against Pharmaceutical Impersonation
Eli Lilly’s successful strategy relied on demonstrating a clear nexus between the disputed domain and the unauthorized sale of medical products. By highlighting that the respondent’s domain name fully incorporated the MOUNJARO trademark, the complainant established confusing similarity, successfully arguing that the inclusion of the descriptive term ‘caneta’ (Portuguese for ‘pen’) did not mitigate consumer confusion. This approach was further bolstered by evidence showing that the respondent lacked any rights or legitimate interests in the domain, given the complete absence of authorization from the complainant to distribute its pharmaceutical preparations.
The case was ultimately won by presenting a comprehensive evidentiary trail of bad faith registration and use. The complainant provided detailed evidence that the associated website impersonated ‘Eli Lilly Brasil’ to market counterfeit medications without prescription requirements. Crucially, the discovery of AI-generated content—specifically misspellings of the brand name such as ‘mouryaro’—and the use of fraudulent contact information served as definitive proof of the respondent’s malicious intent to deceive patients. This evidence underscored the risk of brand dilution and the immediate danger to consumer safety, compelling the panel to order the transfer of the domain.
Practical Recommendations
- Implement automated brand monitoring to detect domain registrations that combine core trademarks with descriptive localized terms like ‘caneta’ (pen) to preemptively identify regional storefront threats.
- Develop a rapid-response workflow for identifying AI-generated inconsistencies, such as brand misspellings (e.g., ‘mouryaro’), which serve as high-confidence indicators of fraudulent pharmaceutical sites.
- Direct consumer awareness efforts toward official communication channels by prominently displaying verifiable contact details and warning users against purchasing medication from unauthorized third-party domains.
- Prioritize evidence collection of ‘bad faith’ usage, such as unauthorized claims of corporate affiliation or the absence of legitimate contact details, to streamline the UDRP filing process.
- Establish a proactive takedown strategy for counterfeit marketplaces that includes documenting the specific visual imitation of corporate branding, as this evidence is critical for establishing bad faith under the Policy.
Frequently Asked Questions (FAQ)
Why was the domain ‘canetamounjaro.shop’ considered confusingly similar to Eli Lilly’s trademark?
The WIPO panel determined that the disputed domain entirely incorporates the ‘MOUNJARO’ trademark. The addition of the Portuguese term ‘caneta’ (meaning ‘pen’) does not distinguish the domain from the official brand, but rather suggests a specific version of the product, creating a high risk of consumer confusion.
How did the panel establish that the respondent acted in bad faith?
The panel found bad faith based on the respondent’s clear awareness of the MOUNJARO trademark at the time of registration, combined with the malicious use of the site to impersonate ‘Eli Lilly Brasil’ and sell counterfeit products. Furthermore, the respondent failed to provide a rebuttal to the complaint.
What indicators were used to identify the website as a fraudulent shop?
Evidence showed the site operated as a fake storefront offering counterfeit drugs without prescriptions. Key indicators included the use of AI-generated product imagery containing misspellings (such as ‘mouryaro’), the use of non-legitimate contact information, and unauthorized claims of being an official pharmaceutical distributor.
What is the practical outcome of this UDRP decision for the business?
The panel ordered the transfer of the domain ‘canetamounjaro.shop’ to Eli Lilly and Company. This action effectively shuts down the fraudulent storefront, mitigating the immediate health and safety risks to consumers and preventing further brand dilution caused by the unauthorized impersonation.
Is a fake shop putting your customers at risk?
As seen in the Eli Lilly case, attackers are using sophisticated impersonation and AI-generated content to distribute counterfeit pharmaceuticals. If you have identified websites misusing your brand to deceive consumers, our team can help you assess your UDRP eligibility to secure your digital presence.
This case note is for informational purposes only and is not legal advice.
